Cabaletta Bio, Inc.

Equities

CABA

US12674W1099

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-15 pm EDT			5-day change	1st Jan Change
7.81 ^USD	-5.22%		+3.31%	-65.59%

Jun. 14	Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday	MT
Jun. 14	Sector Update: Health Care	MT

Cabaletta Bio Inc. announced that it expects to receive $49.999998 million in funding

January 01, 2019

Cabaletta Bio Inc. announced that it will receive $49,999,998 in funding on January 2, 2019. The company will issue common shares in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.

Latest news about Cabaletta Bio, Inc.

Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday	Jun. 14	MT
Sector Update: Health Care	Jun. 14	MT
Transcript : Cabaletta Bio, Inc. - Special Call	Jun. 14
Cabaletta Bio Says Autoimmune Disease Therapy Showed Promise in Early Results	Jun. 14	MT
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis? and RESET-SLE? Trials of CABA-201	Jun. 14	CI
Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating	Mar. 22	MT
Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Cabaletta Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
Cabaletta Bio Gets Orphan Drug Designation From FDA For Systemic Sclerosis Treatment	Mar. 20	MT
North American Morning Briefing : Markets on Hold -2-	Mar. 20	DJ
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
Jefferies Initiates Cabaletta Bio with Buy Rating, $36 Price Target	Feb. 05	MT
Cabaletta Bio Secures Orphan Drug Designation for Myositis Treatment	Feb. 02	MT
Cabaletta Bio Gets Orphan Drug Designation for Potential Autoimmune Disease Treatment	Feb. 01	DJ
Cabaletta, Inc. Announces FDA Grants Orphan Drug Designation to CABA-201	Feb. 01	CI
Transcript : Cabaletta Bio, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 05:15 PM	Jan. 09
Cabaletta Bio Gets Additional FDA Fast Track Labels For CABA-201	Jan. 08	MT
Cabaletta Bio, Inc. Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis	Jan. 08	CI
Cabaletta Bio, Inc.(NasdaqGS:CABA) added to NASDAQ Biotechnology Index	Dec. 18	CI
Morgan Stanley Cuts Price Target on Cabaletta Bio to $25 From $28 as FDA Probes T-Cell Malignancies in CAR-T Cell Therapy, Keeps Overweight Rating	Nov. 29	MT
Health Care Down as FDA Probes Immunotherapy Treatments -- Health Care Roundup	Nov. 28	DJ
Sector Update: Health Care Stocks Retreat in Late Afternoon	Nov. 28	MT
Sector Update: Health Care	Nov. 28	MT
Cabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T Drugs	Nov. 28	DJ

Chart Cabaletta Bio, Inc.

Duration

Period

More charts

Company Profile

Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.81 USD

Average target price

33.56 USD

Spread / Average Target

+329.65%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CABALETTA BIO, INC.	-65.59%	398M
VERTEX PHARMACEUTICALS INCORPORATED	+20.63%	126B
ARGENX SE	+24.16%	27.95B
BIONTECH SE	-20.17%	20.5B
GENMAB A/S	-16.06%	17.12B
BEIGENE, LTD.	-18.07%	16.1B
WUXI APPTEC CO., LTD.	-47.70%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.92%	14.84B
SAREPTA THERAPEUTICS, INC.	+58.32%	14.38B
INSMED INCORPORATED	+149.98%	12.37B

Bio Therapeutic Drugs